论文部分内容阅读
癌胚抗原(CEA)自1965年Gold和Freedman初次发现以来,已被公认为肿瘤的标志并已广泛应用于对消化道肿瘤的诊断和预后监测。为测定它在肿瘤诊断方面的价值究竟如何?我们检测了684例不同肿瘤患者的血清癌胚抗原,现将检测结果报道如下。材料与方法一、CEA放射免疫试剂盒(双抗体+PEG法,系四川五洲同位素研究所产品)。二、实验操作基本参照试剂盒说明书进行,部份样品采用“半量法”测定,即各试剂用量比试剂盒指定用量减半。测量中使用的Fj2008自动r免疫计数器系西安262工厂产品。三、各试剂用全量与用半量的质控参数对照见表1。四、本试剂盒的检测范围是(5～80ng/
Carcinoembryonic antigen (CEA) has been recognized as a tumor marker since its first discovery by Gold and Freedman in 1965 and has been widely used in the diagnosis and prognosis monitoring of digestive tract tumors. In order to determine its value in tumor diagnosis, we tested 684 serum carcinoembryonic antigens in patients with different tumors. The test results are reported below. Materials and Methods 1. CEA radioimmunoassay kit (double antibody + PEG method, Sichuan Wuzhou Institute of isotope products). Second, the experimental operation is basically carried out with reference to the kit instructions. Some samples are measured by the “half-measure method”, that is, the amount of each reagent is halved compared to the amount specified by the kit. The Fj2008 automatic immuno-counter used in the measurement was a Xi’an 262 factory product. Third, the use of the full amount of each reagent and control parameters with half the amount of control in Table 1. Fourth, the test range of this kit is (5 ~ 80ng/